Strength of patient cohorts and biobanks for cardiomyopathy research

Boer, Rudolf A. de; Nijenkamp, Louise L.A.M.; Silljé, Herman H W; Eijgenraam, Tim R.; Parbhudayal, Rahana Y.; Driel, Beau van; Huurman, Roy; Michels, Michelle; Pei, Jiayi; Harakaľová, Magdaléna; Lint, Freyja H.M. van; Jansen, Manon A. A.; Baas, Annette F.; Asselbergs, Folkert W.; Tintelen, J. Peter van; Brundel, Bianca J. J. M.; Dorsch, Larissa M.; Schuldt, Maike; Kuster, Diederik W.D.; Velden, Jolanda van der

doi:10.1007/s12471-020-01456-4

Cited by 1 publication

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subjects are included as part of the ongoing prospective, multicentre, longitudinal, observational BIO FOr CARe cohort, embedded in the CVON DOSIS (Cardiovascular Research Netherlands—Determinants Of Susceptibility In inherited cardiomyopathy: towards novel therapeutic approacheS) consortium [ 19 ]. The design of this study is illustrated in Fig.…”

Section: Methodsmentioning

confidence: 99%

BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Hypertrophic cardiomyopathy (HCM) is the most prevalent monogenic heart disease, commonly caused by truncating variants in the MYBPC3 gene. HCM is an important cause of sudden cardiac death; however, overall prognosis is good and penetrance in genotype-positive individuals is incomplete. The underlying mechanisms are poorly understood and risk stratification remains limited. Aim To create a nationwide cohort of carriers of truncating MYBPC3 variants for identification of predictive biomarkers for HCM development and progression. Methods In the multicentre, observational BIO FOr CARe (Identification of BIOmarkers of hypertrophic cardiomyopathy development and progression in Dutch MYBPC3 FOunder variant CARriers) cohort, carriers of the c.2373dupG, c.2827C > T, c.2864_2865delCT and c.3776delA MYBPC3 variants are included and prospectively undergo longitudinal blood collection. Clinical data are collected from first presentation onwards. The primary outcome constitutes a composite endpoint of HCM progression (maximum wall thickness ≥ 20 mm, septal reduction therapy, heart failure occurrence, sustained ventricular arrhythmia and sudden cardiac death). Results So far, 250 subjects (median age 54.9 years (interquartile range 43.3, 66.6), 54.8% male) have been included. HCM was diagnosed in 169 subjects and dilated cardiomyopathy in 4. The primary outcome was met in 115 subjects. Blood samples were collected from 131 subjects. Conclusion BIO FOr CARe is a genetically homogeneous, phenotypically heterogeneous cohort incorporating a clinical data registry and longitudinal blood collection. This provides a unique opportunity to study biomarkers for HCM development and prognosis. The established infrastructure can be extended to study other genetic variants. Other centres are invited to join our consortium.

show abstract

Section: Methodsmentioning

confidence: 99%